InsidersTradesSigma
Total declarations
Companies
▲ Purchases (2 ops.)
▼ Sales (0 ops.)
Discover the detailed record of transactions filed by Posard Matthew L., Director. Director active across 3 companies, notably Halozyme Therapeutics, INC.. Aggregated, 8 filings have been logged. Total volume traded: €162k. The latest transaction was filed on 26 May 2022 (Attribution). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations8 total
026,480 shares0
Common Stock
SEC:0001209191-22-032989:0·
06,206 shares0
Restricted Stock Units
SEC:0001179110-22-002912:0·
€80,93220,000 shares@ €4.0466100.0% of flow
Common Stock
SEC:0001808805-21-000026·
Ideal exit: 27 Aug 2022 (T+270)
€80,93220,000 shares@ €4.04660.033% mcap50.0% of flow
Common Stock
SEC:0001808805-21-000026:0·
Ideal exit: 27 Aug 2022 (T+270)
04,497 shares0
Common Stock
SEC:0001209191-21-036712·
04,497 shares0
Common Stock
SEC:0001209191-21-036712:0·
5,230 shares
Restricted Stock Units
SEC:0001179110-21-004974·
05,230 shares0
Restricted Stock Units
SEC:0001179110-21-004974:0·
8 of 8 declarations
About Posard Matthew L.
Posard Matthew L. is a Director at HALOZYME THERAPEUTICS, INC., DermTech, Inc., and Nautilus Biotechnology, Inc. He plays a key role in the governance of these companies, contributing to strategic decision-making and overseeing operations. His experience in the biopharmaceutical sector is a valuable asset.
